Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.52M
Average 1.55M
ORKA EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Oruka Therapeutics, Inc.NASDAQ: ORKA
EPS (Basic) · Q3 FY2026 · quarter ended Sep 2026
EPS (Basic) remains negative
Q3 FY2026 EPS (Basic) was -$0.63, compared with -$0.69 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.41.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 7 analysts of -$2.11 (+8.5%) for the fiscal year ending Dec 2026, a slowdown from the +53.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$0.63+4.5% QoQ
- Last fiscal yearDec 2025
- -$2.31+53.7% YoY
- LTMSep 2026
- -$2.41+27.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.7% | -1.7% | -10.4 pp |
| 1 year | +53.7% | +8.5% | -45.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (2.31) USD
- Year-over-year change
- +53.7%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.31) | +53.7% |
| FY2024 | 2024-12-31 | (4.99) | -12.4% |
| FY2023 | 2023-12-31 | (4.44) | +46.3% |
| FY2022 | 2022-12-31 | (8.27) | +50.4% |
| FY2021 | 2021-12-31 | (16.68) | — |
EPS (Basic) vs competitors
How ORKA compares with its peers on the latest reported figures
- ORKA's LTM Sep 2026 EPS (Basic) of -$2.41 is the 8th highest of the 10 companies compared; the peer median is -$1.09.
- Its year-over-year change of +27.2% is the 4th highest of 10, against a peer median of +13.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | -$0.13 | +96.0% | — | |
| LTM Mar 2026 | -$0.56 | +59.7% | — | |
| LTM Mar 2026 | -$0.85 | +82.7% | — | |
| FY2025 | -$1 | -257.1% | — | |
ZURAZura Bio Limited | LTM Mar 2026 | -$1.09 | -43.4% | — |
| FY2025 | -$1.42 | -35.2% | — | |
| LTM Jun 2026 | -$2.17 | +13.5% | — | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | -$2.41 | +27.2% | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$3.8 | +15.7% | — |
| LTM Mar 2026 | -$3.88 | -68.7% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
| Peer median (excluding ORKA) | -$1.09 | +13.5% | — | |
Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 91K | 114K | 111K | 27K | 83K |
| Gross Profit | (91K) | (114K) | (111K) | (27K) | (83K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.83M | 4.46M | 1.01M | 75.06M | 100.64M |
| Selling, General & Admin | 5.41M | 5.26M | 6.17M | 13.04M | 21.33M |
| Operating Expenses | 19.24M | 9.73M | 7.19M | 88.1M | 121.97M |
| Depreciation & Amortization | 91K | 114K | 111K | 27K | 83K |
| EBITDA | (19.23M) | (9.81M) | (5.23M) | (82.23M) | (105.35M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.34M) | (9.84M) | (7.3M) | (88.12M) | (122.05M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 675K | 1.96M | 5.86M | 16.63M |
| Interest Expense | 0 | 0 | 0 | 1.47M | 0 |
| Other Income / Expenses | 13K | (85K) | 1.96M | 4.4M | 16.62M |
| Income Before Tax | (19.32M) | (9.93M) | (5.34M) | (83.72M) | (105.43M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.32M) | (9.93M) | (5.34M) | (83.72M) | (105.43M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (16.68) | (8.27) | (4.44) | (4.99) | (2.31) |
| EPS (Diluted) | (16.68) | (8.27) | (4.44) | (4.99) | (2.31) |
| Weighted Avg Shares | 13.9M | 14.41M | 14.42M | 16.79M | 45.61M |
| Weighted Avg Shares (Diluted) | 13.9M | 14.41M | 14.42M | 16.79M | 45.61M |
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$95.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.